Amsterdam-based Leyden Laboratories, a company that aims to protect against a broad range of viruses, has raised €40M in its Series A round of funding led by GV (formerly Google Ventures), with participation from F-Prime Capital, Casdin Capital, LLC and Brook Byers.
Use of the funds
The raised capital will help the company to advance the platform and portfolio of intranasal products that protect against a broad range of respiratory viruses, including influenza and coronaviruses. The funding will also be used to expand its headcounts.